Two-year Data from ViaCyte's STEP ONE Clinical Trial Presented at ADA 2018

SAN DIEGO, June 23, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced two-year data from Cohort 1 of the ongoing Safety, Tolerability, and Efficacy of VC-01™ (PEC-Encap™) Product Candidate in Type One Diabetes (STEP ONE) clinical trial....